KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the KRAS, BRAF, and PIK3CA mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Xin-Hui, Chen, Zhi-Ting, Wang, Wen-Hui, Fan, Xin-Juan, Huang, Yan, Wu, Xiao-Bin, Huang, Jing-Lin, Wang, Jing-Xuan, Lin, Han-Jie, Tan, Xiao-Li, Wang, Lei, Wang, Jian-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400811/
https://www.ncbi.nlm.nih.gov/pubmed/30854087
http://dx.doi.org/10.7150/jca.27899
Descripción
Sumario:This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the KRAS, BRAF, and PIK3CA mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. The results show that the frequency of KRAS, BRAF and PIK3CA mutations were 4.1%, 1.2% and 3.5%, respectively. BRAF mutations were significantly concentrated in stage III and IV gastric cancer (P=0.009). KRAS G12V mutation carriers have much shorter OS than other mutation carriers and wild-type group patients (P=0.013). In conclusion, only the KRAS G12V mutation has an adverse effect on patient survival.

Ejemplares similares